Status:
COMPLETED
Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Lymphoma
Eligibility:
All Genders
20-74 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vorinostat (MK-0683) in participants with relapsed and/or refractory follicular lymphoma. The exploratory purpose of ...
Eligibility Criteria
Inclusion
- Participant has an histopathologically confirmed follicular lymphoma (FL), or other indolent B-cell non-Hodgkin's lymphoma (B-NHL) or mantle cell lymphoma (MCL)
- Only relapsed/refractory FL can be included outside Japan
- Participant has at least one measurable lesion by computerized tomography (CT) scan which is defined by Cheson's 1999 criteria
- Participant has received at least 1 but up to 4 prior chemotherapeutic regimens, the most recent therapy must have failed to induce a partial response, or there must be recurrence in case of the most recent therapy has shown complete response, or there must be relapse in case of the most recent therapy has shown partial response
- Life expectancy of \>4 months
- Participant must have adequate organ and marrow function
- Women of child bearing potential must be negative for pregnancy and agree to use effective contraceptive measures until 30 days after the last dose of MK-0683.
- Men must agree to use effective contraceptive measures until 6 months after the last dose of MK-0683
Exclusion
- Participant has undergone allogenic transplant treatment or autologous stem cell transplant within 6 months
- Participant with other active malignancies or central neurological infiltration with lymphoma
- Participant with severe hepatic insufficiency
- Participant with history of allergic reactions attributed to any component of MK-0683
- Participant is known to be human immunodeficiency virus (HIV) antibody-, hepatitis B virus antigen- or hepatitis C virus antibody-positive
- Participant has undergone prior/concomitant treatment with MK-0683 or other histone deacetylase (HDAC) inhibitors
Key Trial Info
Start Date :
April 15 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 8 2019
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00875056
Start Date
April 15 2009
End Date
February 8 2019
Last Update
October 29 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.